

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
29 September 2022 (29.09.2022)



(10) International Publication Number
WO 2022/200493 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C12N 15/74 (2006.01)
C07K 16/28 (2006.01)

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(21) International Application Number:

PCT/EP2022/057752

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(22) International Filing Date:

24 March 2022 (24.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21164882.9 25 March 2021 (25.03.2021) EP

(71) Applicant: T3 PHARMACEUTICALS AG [CH/CH]; c/o Biozentrum, Universität Basel, Klingelbergstrasse 50/70, 4056 Basel (CH).

(72) Inventors: ITTIG, Simon; Zehntenfreistrasse 32, 4103 Bottmingen (CH). KASPER, Christoph; Ruttigerweg 4, 4600 Olten (CH). SAUPE, Falk; Schorenweg 38, 4058 Basel (CH). AMSTUTZ, Marlise; Wittlingerstrasse 140, 4058 Basel (CH). DUVAL, Mélodie; 13, rue du port, 68330 Huningue (FR).

(74) Agent: SCHÖLLHORN, Andreas; Latscha Schöllhorn Partner AG, Grellingerstrasse 60, 4052 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER

(57) Abstract: The present invention relates to a pharmaceutical combination comprising a recombinant Gram-negative bacterial strain and an immune checkpoint modulator (ICM) and their use in a method for the prevention, delay of progression or treatment of cancer in a subject.

WO 2022/200493 A1